	US 11,667,717 B2
	Antibodies binding to human IL-4R, preparation method therefor and use thereof
Jie Zhao, Shanghai (CN); Liangfeng Jiang, Shanghai (CN); Chen Chen, Shanghai (CN); Huiling Wu, Shanghai (CN); Yuping Huang, Shanghai (CN); Haomin Huang, Shanghai (CN); and Zhenping Zhu, Shanghai (CN)
Assigned to SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD., Shanghai (CN)
Appl. No. 17/45,285
Filed by SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD., Shanghai (CN)
PCT Filed Aug. 20, 2019, PCT No. PCT/CN2019/101628 § 371(c)(1), (2) Date Oct. 5, 2020, PCT Pub. No. WO2020/048312, PCT Pub. Date Mar. 12, 2020.
Claims priority of application No. 201811023880.9 (CN), filed on Sep. 4, 2018.
Prior Publication US 2021/0206861 A1, Jul. 8, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2866 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)]

12 Claims

1. An antibody or antigen-binding fragment thereof that binds to human IL-4 receptor (IL-4R), wherein said antibody or antigen-binding fragment thereof comprises:

(1) heavy chain complementarity determining regions HCDR1, HCDR2, HCDR3, wherein the HCDR1 having the amino acid sequence as shown in SEQ ID NO: 6, the HCDR2 having the amino acid sequence as shown in SEQ ID NO: 7, and the HCDR3 having the amino acid sequence as shown in SEQ ID NO: 8, and

(2) light chain complementarity determining regions LCDR1, LCDR2, LCDR3, wherein the LCDR1 having the amino acid sequence as shown in SEQ ID NO: 9, the LCDR2 having the amino acid sequence as shown in SEQ ID NO: 10, and the LCDR3 having the amino acid sequence as shown in SEQ ID NO: 11.